DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Urelumab is an investigational drug.
There have been 7 clinical trials for Urelumab. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2016.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Carcinoma, Transitional Cell, and Multiple Myeloma. The leading clinical trial sponsors are Bristol-Myers Squibb, University of Chicago, and Sidney Kimmel Comprehensive Cancer Center.
There are twenty-five US patents protecting this investigational drug and two hundred and forty-seven international patents.
Recent Clinical Trials for Urelumab
|Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors||Clinica Universidad de Navarra, Universidad de Navarra||Phase 1/Phase 2|
|Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer||Bristol-Myers Squibb||Phase 1|
|Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer||University of Chicago||Phase 1|
Top disease conditions for Urelumab
Top clinical trial sponsors for Urelumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Urelumab||Get Started Free||Immunoregulatory agents||Flexus Biosciences, Inc. (Princeton, NJ)||Get Started Free|
|Urelumab||Get Started Free||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Get Started Free|
|Urelumab||Get Started Free||Constructs having a SIRP-.alpha. domain or variant thereof||ALX ONCOLOGY INC. (Burlingame, CA)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Urelumab||Argentina||AR102536||2034-11-05||Get Started Free|
|Urelumab||Australia||AU2015342940||2034-11-05||Get Started Free|
|Urelumab||Brazil||BR112017008568||2034-11-05||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|